Get the Stockscreener App
38.86
5.54%
-2.28
Viking Therapeutics Inc stock is traded at $38.86, with a volume of 2.16M.
It is down -5.54% in the last 24 hours and up +40.04% over the past month.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
See More
Previous Close:
$41.14
Open:
$41.14
24h Volume:
2.16M
Relative Volume:
0.91
Market Cap:
$4.51B
Revenue:
-
Net Income/Loss:
$-472.34M
P/E Ratio:
-9.3731
EPS:
-4.1459
Net Cash Flow:
$-340.33M
1W Performance:
+3.79%
1M Performance:
+40.04%
6M Performance:
+21.48%
1Y Performance:
+24.19%
1-Day Range:
$38.18
$41.14
1-Week Range:
$37.10
$42.79
52-Week Range:
$22.96
$43.15
Viking Therapeutics Inc Stock (VKTX) Company Profile
Name
Viking Therapeutics Inc
Sector
Industry
Phone
858-704-4660
Address
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Compare VKTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
38.86 | 4.51B | 0 | -472.34M | -340.33M | -4.1459 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-26-26 | Initiated | Wolfe Research | Peer Perform |
| Oct-29-25 | Initiated | Canaccord Genuity | Buy |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-08-25 | Initiated | Goldman | Neutral |
| Feb-13-25 | Initiated | Scotiabank | Sector Outperform |
| Feb-07-25 | Initiated | Citigroup | Neutral |
| Dec-02-24 | Initiated | Piper Sandler | Overweight |
| Nov-22-24 | Initiated | B. Riley Securities | Buy |
| Nov-04-24 | Reiterated | H.C. Wainwright | Buy |
| Sep-11-24 | Initiated | JP Morgan | Overweight |
| Jun-27-24 | Initiated | Morgan Stanley | Overweight |
| May-16-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-26-24 | Reiterated | Oppenheimer | Outperform |
| Mar-07-24 | Initiated | Jefferies | Buy |
| Feb-28-24 | Reiterated | Oppenheimer | Outperform |
| May-31-23 | Resumed | ROTH MKM | Buy |
| Mar-28-23 | Reiterated | Maxim Group | Buy |
| Mar-17-23 | Initiated | Stifel | Buy |
| Jul-29-21 | Resumed | BTIG Research | Buy |
| May-25-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Jun-05-20 | Initiated | BMO Capital Markets | Outperform |
| May-05-20 | Initiated | Chardan Capital Markets | Buy |
| May-01-20 | Initiated | BTIG Research | Buy |
| Jul-16-19 | Initiated | Oppenheimer | Outperform |
| Jun-25-19 | Initiated | Stifel | Buy |
| Mar-29-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-14-19 | Reiterated | Maxim Group | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Mkt Perform |
| Dec-12-18 | Initiated | B. Riley FBR | Buy |
| Nov-19-18 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-18-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-18-18 | Reiterated | Maxim Group | Buy |
| Sep-18-18 | Reiterated | Raymond James | Outperform |
| Jul-20-18 | Initiated | SunTrust | Buy |
| Jun-28-18 | Initiated | Raymond James | Outperform |
| Jun-01-18 | Reiterated | Laidlaw | Buy |
| May-31-18 | Reiterated | Maxim Group | Buy |
| Mar-26-18 | Resumed | H.C. Wainwright | Buy |
| Nov-28-17 | Reiterated | Maxim Group | Buy |
| Nov-21-17 | Initiated | ROTH Capital | Buy |
View All
Viking Therapeutics Inc Stock (VKTX) Latest News
Is Viking Therapeutics Poised to Disrupt the Weight-Loss Market - Kavout | AI
A New GLP-1 Challenger? Early Data Shows Viking's New Obesity Drug Tops Novo Rival - Stocktwits
VKTX Stock Rises After-Hours: CNBC Flags Viking As Likely Buyout Target This Year As Big Pharma Hunts Next GLP-1 Winner - Stocktwits
Viking Therapeutics, Inc. (VKTX) stock falls amid market uptick: What investors need to know - MSN
Viking Therapeutics, Inc. (VKTX) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance
Does Viking Therapeutics (VKTX) Expanding Into Dual-Agonist Obesity Drugs Reframe Its Long-Term Pipeline Strategy? - Sahm
(VKTX) Risk Channels and Responsive Allocation - Stock Traders Daily
Here’s How Much You Would Have Made Owning Viking Therapeutics Stock In The Last 10 Years - Benzinga
Viking Therapeutics: Still Cheap, But Watch Double Top (NASDAQ:VKTX) - Seeking Alpha
CRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - AOL.com
Is Viking Therapeutics Stock Going to $100? - AOL.com
Here's Why Viking Therapeutics Stock Surged Higher in June - AOL.com
Viking Therapeutics (VKTX) Price Forecast: Bottoming Pattern Signals Growing Strength - FXEmpire
Is This Biotech Stock a Buy After Its Massive Rally? - The Motley Fool
How Much Could $1,000 Invested in Viking Therapeutics Be Worth by 2030? - AOL.com
Buyout Buzz Around VKTX Is Back: What's Fueling the Speculation? - Yahoo Finance
VKTX Stock Draws Fresh Attention Ahead Of Earnings: Wall Street Sees Over 170% Upside As GLP-1 Race Burns Hot - Stocktwits
Is Viking Therapeutics the Ultimate Millionaire-Maker Obesity Stock for 2026? - AOL.com
Why Viking Therapeutics, Inc. (VKTX) Dipped More Than Broader Market Today - Yahoo Finance
Better Weight Loss Drug Stock Buy: Eli Lilly vs Viking Therapeutics - AOL.com
VKTX Stock Extends Red-Hot Streak: Insider Scoops Up Shares As Multiple Phase 3 Trials Loom This Year In Obesity Race - Stocktwits
VKTX Eyes Worst Week Since November As Trial Data Looms — Wall Street Still Sees 200% Upside - Stocktwits
Is It Too Late to Buy Eli Lilly? - The Motley Fool
LLY Hits Another Record High: Is the Stock Too Expensive to Buy Now? - TradingView
Viking Therapeutics (VKTX) Stock Looks Stretched After a 6x Five Year Run - Yahoo Finance
Viking Therapeutics (VKTX) Stock Looks Pricey After New Obesity Trial Launch - simplywall.st
Piper Sandler Sticks to Its Buy Rating for Viking Therapeutics (VKTX) - The Globe and Mail
Viking Therapeutics, Inc. (VKTX) Stock Price Quote Today & Current Price Chart - Capital.com
Viking Therapeutics (VKTX) Draws Takeover Focus After Vertex's $10 Billion Crinetics Deal - Yahoo Finance
Viking Therapeutics (VKTX) Could Be 120% Undervalued On Obesity Pipeline Progress - Yahoo Finance
Viking Therapeutics (VKTX) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Why Viking Therapeutics (VKTX) Is Up 8.0% After Advancing New Obesity Drug VK3019 Into Phase 1 – And What's Next - Yahoo Finance
VKTX Vs BCRX: Which Biotech Takeover Favorite Offers More Upside After Vertex’s $10B CRNX Deal? - Yahoo Finance
Viking Therapeutics Gains as Obesity Pipeline Momentum Builds - Quiver Quantitative
Viking Therapeutics (VKTX) Q2 2024 earnings summary - Quartr
Viking Therapeutics (VKTX) Proxy filing Summary - Quartr
Viking Therapeutics (VKTX) Corporate presentation Summary - Quartr
Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical Officer - AOL.com
CRISPR Therapeutics vs. Viking Therapeutics: Is a Gene-Editing or Weight Loss Focused Stock Is a Better Buy in 2026? - The Motley Fool
Piper Sandler reiterates Overweight on Viking Therapeutic stock By Investing.com - Investing.com Nigeria
Piper Sandler reiterates Overweight on Viking Therapeutic stock - Investing.com
VKTX Stock Has Nearly 300% Wall Street Upside — Is Viking’s Oral Obesity Pill The Next Novo Nordisk-Style Breakout? - Stocktwits
Piper Sandler Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $71 - Moomoo
Viking Therapeutics (VKTX) Starts VK3019 Trial As Obesity Pipeline Narrative Meets Valuation - simplywall.st
Viking Therapeutics (NASDAQ: VKTX) Faces Uphill Battle In $150 Billion GLP-1 Race Toward 2030 - foreignpolicyjournal.com
OABI,VKTX Revenue Breakdown - Finviz
Could This Healthcare Stock Help You Build a Real Fortune Over the Next 20 Years? - Yahoo Finance
VKTX Stock Rallies After Hours On Optimism Around Company’s Obesity Pipeline - Stocktwits
VKTX Stock Outpaces LLY, ALT Ahead Of Earnings – Retail Eyes Breakout Ahead - Stocktwits
Quick ratio of Viking Therapeutics, Inc. – XETR:1VT - TradingView
Viking Therapeutics' Prospects in the Weight Loss Drug Market - Intellectia AI
Viking Therapeutics Inc Stock (VKTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):